Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.

For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the development of the company’s Covid-19 vaccine was purposefully delayed until after the 2020 presidential election.

As of April 26, about 14% of pregnant women and 13% of children had received the updated COVID vaccine, according to the CDC. In the U.S., three COVID shots have been authorized for use - Moderna and Pfizer-BioNTech's/ messenger RNA based vaccines along with Novavax's protein-based shot.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Today,

The House Judiciary Committee, led by Republicans, has accused Pfizer of engaging in a “massive scandal” related to its COVID-19 vaccine trial data, alleging the company deliberately delayed results to influence the 2020 presidential election.

WASHINGTON (Reuters) -U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research executives intentionally delayed clinical trial results of its COVID-19 vaccine to influence the 2020 presidential election.

New FDA framework on changes coronavirus vaccine approval will be released “in the coming days,” FDA Commissioner Marty Makary said Thursday.

But the political situation has changed for the ... vaccines today are placebo-tested (including the original covid-19 vaccines), it’s unclear whether this order will also apply to vaccines ...

Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet h

By Kamal Choudhury (Reuters) -Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some investor concerns over the future of the shot.